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Background: Current guidelines for treatment-resistant depression in adolescents remain inadequate. This study
aimed to systematically review the management of treatment-resistant depression in adolescent patients.
Methods: We conducted an electronic database search of PUBMED, EMBASE, Cochrane, Web of Science and
PsycINFO for studies with adolescent treatment-resistant depression published up to January 2014. Treatment-
resistant depression was defined as failure to respond to at least one course of psychological or pharmacological
treatment for depression with an adequate dosage, duration, and appropriate compliance during the current illness
episode. The Cochrane risk-of-bias method was used to assess the quality of randomized controlled trials. A
meta-analysis of all active treatments was conducted.
Results: Eight studies with 411 depressed adolescents that fit predetermined criteria investigated pharmacological
treatments and psychotherapies. Six were open-label studies, and two were randomized controlled trials. The overall
response rate for all active treatments investigated was 46% (95% CI 33 to 59; N = 411) with a moderately high
degree of heterogeneity (I2 = 76.1%, 95% CI = 47%-86%). When only the two randomized trials were included, the
overall response rate of active treatment was 53% (95% CI = 38-67; N = 347). In these randomized trials, SSRI therapy
plus CBT was significantly more effective than SSRI therapy alone, while amitriptyline was not more effective than
placebo.
Conclusions: Approximately half of the adolescents who presented with treatment-refractory depression responded
to active treatment, which suggests that practitioners should remain persistent in managing these challenging
cases. The combination of antidepressant medication and psychotherapy should be recommended for adolescents
who present with treatment-resistant depression.
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Depression in adolescents is a major public health problem
with an estimated point prevalence of about 2-5% among
teens between 13 and 18 years of age. Approximately 20%
of adolescents experience at least one episode of major de-
pression before adulthood [1,2]. Despite advances in the
treatment of depression in adolescents (e.g., medication,
psychotherapy), it is estimated that 30% to 40% of patients
do not show an adequate clinical response to the initial* Correspondence: xiepeng973@126.com
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unless otherwise stated.treatment when defined as at least a 50% reduction in
symptoms. Fava M, 2003 [3,4] Adolescents who do not re-
spond to an adequate initial treatment dosage, termed
treatment-resistant depression (TRD), have a high likeli-
hood of recurrence into adulthood [5], and compared with
these non-refractory patients, display higher suicide rates,
more serious impairments in social functioning, worse
school achievement, and more relational problems with
family members and peers [6-8].
Many studies have been conducted in the field of adult
depression, and there are some similarities between ado-
lescent and adult depression; for example, cognitive-
behavioral therapy (CBT) and selective serotonin reuptake
inhibitors (SSRIs) are routinely used to treat both adultstd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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substantiated differences between these two populations;
for example, there are higher odds of a family history of
psychopathology and developmental problems in adoles-
cents [11,12]. For the management of adult TRD, two
main strategies have been proposed – switching to another
therapeutic class or augmentation. These two strategies
are generally considered to be relevant to different popula-
tions – non-responders and partial responders, respect-
ively [13,14]. Partial or non-responses to conventional
treatments for depression may be moderated or mediated
by the presence of stressors such as losses, abuse, neglect,
and ongoing conflicts and frustrations. Moreover, the ef-
fects of these stressors also depend on the adolescents’
negative attributional styles for interpreting and coping
with stress, available support systems, and genetic factors
[15]. Other factors – such as the presence of comorbid
disorders (e.g., anxiety, substance abuse, ADHD, eating
disorders), medical illness, medication use/abuse, bio-
logical factors, and sociocultural factors – have also been
associated with the development and maintenance of de-
pressive symptomatology [16-18].
Furthermore, given that adolescents typically show a
lower and potentially slower response rate to antidepres-
sants as compared to adults, there is ample justification
to analyze the management of depressed adolescents
separately from adults [19-21]. Unfortunately, there is a
paucity of data on the clinical management of adolescent
patients with TRD. A previous review of TRD in adoles-
cents examined a total of six studies (i.e., five open-label
trials and one randomized controlled trial) [22]. How-
ever, the review was not comprehensive or systematic
and the generalizability of the findings was limited.
In light of the prevalence and adverse consequences of
adolescent TRD (e.g., suicide), the importance of having
updated clinical data on the management of TRD in
teens cannot be overstated. However, an up-to-date, sys-
tematic review on the management of TRD in adoles-
cents has not been performed. Therefore, in this review,
we conducted a meta-analytic review of the efficacy of
pharmacological and psychosocial interventions for ado-
lescent TRD.
Methods
Search strategy
We searched five electronic databases (PubMed, Embase,
the Cochrane Library, Web of Science, and PsycINFO)
from inception to January 2014 with Medical Subject
Headings (MeSH) and text words. Additional file 1:
Table S1 includes a detailed systematic search strategy.
We also reviewed the clinical trial registry (clinicaltrials.
gov), the websites of pharmaceutical companies, and rele-
vant reports from the U.S. Food and Drug Administration
(FDA) website. No language restrictions were imposed onthe searches. Additional studies were obtained by scanning
reference lists of relevant reviews and initially eligible
trials.
Selection criteria
We included all primary research evaluating pharmaco-
logical or psychological for adolescent TRD. The partici-
pants were both boys and girls (aged less than 18 years)
with a primary diagnosis of unipolar major depressive dis-
order according to the standardized diagnostic criteria set
forth in the Diagnostic and Statistical Manual of Mental
Disorders (DSM-III [23], DSM-III-R [24], DSM-IV [25]).
We defined TRD as those who failed to respond to at least
one psychological or pharmacological treatment for de-
pression with an adequate dosage, duration, and appropri-
ate compliance for the particular episode [3]. We excluded
trials with duplicate secondary analyses, bipolar depres-
sion, single case reports, physical treatments, or studies
lacking useable data.
Outcome measures
We defined outcomes dichotomously as the proportion
of patients who responded to the treatment (or placebo
or control where appropriate). Response was defined as
a reduction of at least 50% in the score of depression
rating scales [26], such as Children Depression Rating
Scale-Revised (CDRS-R) [27] and Hamilton Depression
Rating Scale (HAMD) [28], or rating as “1” (very much
improved) or “2” (much improved) in the Clinical Global
Impression-Improvement Scale (CGI-I) [29].
Data extraction
Two authors (BQ and YYL) independently reviewed the ti-
tles and abstracts, updated the search by reviewing refer-
ences, identified full-text articles by the same eligibility
criteria, and completed a standardized data extraction
form. Any disagreements were resolved by another review
author (XYZ). We also assessed the methodological quality
of randomized controlled studies (RCTs) using the risk of
bias assessment tool from the Cochrane Handbook [30].
Statistical analysis
We performed a meta-analysis of all active treatments
and used the StatsDirect software package (version 2.8.0,
Cheshire, UK) to analyze the data. We calculated the I2
statistic, which estimates the percentage of variation
across studies that is due to heterogeneity rather than
chance [31]. We decided to use a random-effects model
since there was expected clinical diversity in these differ-
ent treatments. We performed a funnel plot to examine
publication bias and computed the Egger statistic as an
indicator of bias [32]. The overall effect sizes were calcu-
lated based on the pooled proportions and 95% confi-
dence intervals (CIs) for any given treatment. Moreover,
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for any treatment reported by at least two studies separ-
ately. We performed a sensitivity analysis that only in-
cluded randomized controlled trials. We also conducted
a subgroup analysis based on the type of refractory anti-
depressant and another subgroup analysis based on aug-
mentation therapy and switching therapy.
Results
A total of 1039 records were identified through the ini-
tial database search. After excluding 537 duplicate re-
cords, we retrieved 502 potentially relevant studies. Of
these, 377 articles were excluded because or irrelevant
titles and abstracts, and 18 additional articles were iden-
tified as potentially relevant from the references of these
trials and relevant reviews. Then, 135 citations were ex-
cluded after two reviewers independently read the full
texts (BQ and YYL). Among these, we also excluded one
trial because its definition of TRD did not meet our cri-
terion [33]. Finally, eight studies including 411 patients
[34-41] met all our inclusion criteria and were included
in the systematic review (Figure 1).
Description of included studies
The Table 1 summarizes the characteristics and out-
comes of each trial. The trials were published between
1988 and 2011. The sample size ranged from 5 to 334
patients, with a mean sample size of 51 per trial, and the
mean age of participants was 15.9 years (range 12–18Figure 1 Literature search.years). Six studies defined TRD as failure to respond to
one antidepressant, and two studies defined TRD failure
to respond to at least two antidepressants and/or psycho-
therapies. Most trials recruited convenience participants
not designed to be epidemiologically representative of an
underlying population. Only two studies provided infor-
mation about patients who were referred but did not par-
ticipate, reporting about one-tenth of those potentially
eligible participated (33/380 and 334/3258). All studies,
with the exception of the one including only females, in-
volved both female and male patients, and the overall
female-to0male ratio was approximately 2.4:1.
Quality of literature
Of the eight included studies, only two studies were RCTs,
which were rated as being of high-quality. The other six
studies were described as open-label studies, which were
judged to be of lower-quality. Additional file 2: Figure S1
shows the quality of these two RCTs based on the
Cochrane risk-of-bias method. The overall quality of two
RCT studies was rated as good, and most question-based
entries in trials met criteria for low risk of bias. About the
TORDIA study, we regarded the other bias as high risk,
because they changed the treatment options from paroxe-
tine to citalopram. We visually inspected the inverted fun-
nel plots of these eight studies, which appeared to be
approximately symmetrical (Figure 2). Because the total
number of studies was too small to show clear asymmetry,
we performed the Egger test, and the results showed that
the depression outcomes (t = 0.34, P = 0.83) were not in-
fluenced by publication bias.
Efficacy of treatments
The overall response rate for the nine active treatments
(one RCT included two active treatments) investigated
was 46% (95% CI = 33 59, N = 441; Figure 3). The I2 statis-
tic was 76.1% (95% CI = 47%-86%), indicating a moder-
ately high degree of heterogeneity between the studies.
When we included only randomized trials, the overall re-
sponse rate was 53% (95% CI = 38-67, N = 347; Additional
file 3: Figure S2). However, in the placebo controlled trial
[26], there was no significant difference in response rates
between active treatment (76.9%) and placebo (78.6%). In
the subgroup-analysis for the type of refractory anti-
depressant (Additional file 4: Figure S3), the overall
response rate of TCA-resistant TRD was 29% (95% CI =
11-51, N = 49), and the overall response rate of SSRI-
resistant TRD was 51% (95% CI = 39-63, N = 349). In the
13 patients with multi-drug-resistant TRD, the overall
response rate was 75% (95% CI = 50-93, N = 13). In this
review, the treatments for which there was evidence from
at least two studies (Additional file 5: Figure S4) were SSRI
therapy (38%, 95% CI = 15-65, N = 11) and lithium aug-
mentation (24%, 95% CI = 1-61, N = 38). In the other
Table 1 Baseline characteristics and outcomes of included studies
Study Age
(years)
Diagnostic
criteria
Baseline
score
Female
(%)
TRD definition Trial length
(weeks)
Treatment Response
Definition
Measure
outcome
Birmaher [34]* 12-18 DSM-III-R HAMD ≥15 70 Failure to response to
at least two
antidepressants
10 Amitriptyline, 50–300 mg/d
(N = 13); placebo (N = 14)
≥50% reduction in HAMD
score
Amitriptyline: 10/13; placebo:
11/14
Boulos [35] 14-18 DSM-III-R HAMD ≥17 57 Failure to respond to
at least two
consecutive months
with a TCA
6-7 Fluoxetine, 5–40 mg/d (N = 7) ≥50% reduction in HAMD
score
Fluoxetine: 2/5
Brent [36]*
(TORDIA)
12-18 DSM-IV CDRS-R≥ 40 71 Failure to response to
an SSRI regimen for at
least eight weeks
12 A second SSRI (N = 85);
venlafaxine (N = 83); a second
SSRI plus CBT (N = 83);
venlafaxine plus CBT (N = 83)
≥50% reduction in CDRS-R
score
No CBT: CBT = 68/168:91/166
Ghaziuddin [37] 15-18 DSM III-R HAMD ≥11 67 Failure to response to
an adequate trial of a
TCA for at least four
weeks
4-16 Fluoxetine, 20–60 mg/d (N = 6) ≥50% reduction in HAMD
score
Fluoxetine: 2/6
Kondo [38] 13-18 DSM-IV CDRS-R ≥40 100 Failure to response to
fluoxetine treatment
for over eight weeks
8 Augmentation with creatine,
4 g/d (N = 5)
≥50% reduction in CDRS-R
score
Creatine: 3/5
Pathak [39] 13-18 DSM-IV-TR — 60 Failure to respond to
at least an eight-week
trial of an SSRI with
an adequate dose
Case series
(4–16)
Augmentation with
quetiapine, 150–800 mg/d
(N = 10)
CGI-I of 1 or 2 Quetiapine: 7/10
Ryan [40] 14-19 DSM III — 79 Failure to respond to
at least a four-week
trial of a TCA
Case series
(3–16)
Augmentation with lithium,
600–1500 mg/d (N = 14)
CGI-I of 1 or 2 Lithium: 6/14
Strober [41] 13-18 DSM III-R HAMD-21≥
16
71 Failure to response to
imipramine at least six
weeks
3 Augmentation with lithium,
900 mg/d (N = 24)
≥50% reduction in HAMD
score
Lithium: 2/24
Abbreviations: DSM-III DSM-III-R DSM-IV DSM-IV-TR Diagnostic and Statistical Manual of Mental Disorders III version, III revision version, IV version, IV text revision version, CDRS-R Children Depression Rating Scale-Revised,
CGI-S Clinical Global Impressions Severity Subscale, HAMD Hamilton Depression Rating Scale, TRD treatment-resistant depression, SSRI selective serotonin reuptake inhibitor, TCA tricyclic antidepressant, CBT cognitive behavior
therapy, CGI-I Clinical Global Impressions Improvement Subscale.
*Randomized controlled trial (RCT).
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Figure 2 Funnel plot of the included studies examining publication bias. *There was no significant asymmetry detected, indicating that no
publication bias was present.
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therapy was 49% (95% CI = 30-67, N = 53), and the overall
response rate of augmentation therapy was 42% (95% CI
= 14-73, N = 192) (Additional file 6: Figure S5).
Randomized controlled trials
The TORDIA trial [36] evaluated the effects of four ac-
tive treatment groups, including switching to a second
SSRI (paroxetine, citalopram, or fluoxetine, 20–40 mg/
d), switching to venlafaxine (150–225 mg/d), switching
to a different SSRI plus cognitive behavioral therapyFigure 3 Proportional meta-analysis of the included studies with weig(CBT), or switching to venlafaxine plus CBT, in 334 ado-
lescents with SSRI-resistant TRD. Randomization was
assigned to one of four treatment regimens in a 2 × 2
factorial design. The intent was for study participants,
clinicians, and independent evaluators to be blinded to
medication treatment assignment and for independent
evaluators to be blinded to CBT assignment. The CGI-I,
the CDRS-R, Beck Depression Inventory (BDI), Mania
Rating Scale (MRS), and Side Effects Form for Children
and Adolescents were evaluated at baseline and at six
weeks and twelve weeks. The CBT plus a switch tohted response rates and 95% confidence intervals.
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rate (54.8%) than a medication switch alone (40.5%), but
there was no significant difference in response rate be-
tween venlafaxine and a second SSRI (48.2% versus
47.0%). Moreover, there was a greater increase in the
diastolic blood pressure and pulse rate and more fre-
quent occurrence of skin problems during venlafaxine
therapy relative to SSRI therapy. Across all four groups,
three out of ten (30.8%) participants withdrew.
Birmaher et al. [34] compared amitriptyline (50–300 mg/
d) to placebo in 27 depressed adolescents. Randomization
was balanced to match approximately for age (≥15 years
versus <15 years) and sex. Clinicians did not adjust the
dosage based on response and tolerance. Participants and
clinicians were blinded to medication treatment assign-
ment. All patients were evaluated by the HAMD, CGI-I,
BDI, a side effects checklist, and Children’s Global Assess-
ment Scale (CGAS) on a weekly basis during the ten-week
treatment. Interestingly, no statistically significant differ-
ences were found between amitriptyline and placebo in
these outcomes at the point of randomization and at the
end of treatment. Both treatments were well-tolerated, and
the side effects were mildly elevated in the amitriptyline
group.
Open-label studies on antidepressant medications
Fluoxetine was reported in two non-randomized trial.
Boulos et al. [35] reported the effectiveness of fluoxetine
(5–40 mg/day) in an open naturalistic trial. Six of the
seven adolescent patients (85.7%) completed at least six
consecutive weeks of treatment, and one suffered a rash
and withdrew. Ghaziuddin et al. [37] investigated fluoxet-
ine (20–60 mg/day) in an open cross-over trial with six
hospitalized adolescents. Fluoxetine was well-tolerated,
and discontinuation was not necessary in any subject.
Two open studies of tricyclic antidepressant (TCA) re-
fractory depression investigating lithium augmentation
had an identical design. Ryan et al. [40] reported a retro-
spective chart review of 14 adolescents. Six patients
achieved a good response, and no case necessitated its
discontinuation due to side effects from lithium aug-
mentation. Strober et al. [41] conducted a three-week
lithium augmentation trial in 24 adolescents. Lithium
was started at 900 mg and then increased by clinical re-
sponse. The addition of lithium was associated with rela-
tively few side effects.
Pathak et al. [39] augmented antidepressant therapy
with quetiapine (150–800 mg/day, median = 200 mg/day),
in 10 adolescent patients. Doses of pre-existing antide-
pressants remained unchanged during the period of evalu-
ation. Side effects included sedation and weight, and there
was no serious adverse event. Kondo et al. [38] conducted
an open trial of adjunctive creatine with fluoxetine. Five
female adolescents were treated with 4 g/day creatine bymouth for eight weeks. Adverse events were self-limited
with no unresolved treatment-emergent side effects.
Discussion
There is a paucity of systematic evidence to guide practi-
tioners in the management of adolescent TRD despite
the high morbidity and severe impairment in these
young patients. In this review, we found eight studies of
pharmacotherapy or the combination of medication and
psychotherapy that met our inclusion criteria. Our find-
ings indicated that half of adolescents with refractory de-
pression responded adequately and that most treatments
were well-tolerated. One high-quality study suggested
that a combination of a SSRI/SNRI antidepressant and
CBT was significantly more effective than antidepressant
therapy alone [36]. The findings are similar to the more
definitive adult study of treatment resistant depression
(STAR*D) [42].
The current treatment guidelines for the management
of depression in adolescents always start with psycho-
logical education and supportive management followed
by the addition of psychological therapy [12,15,43-45].
Cognitive behavioral therapy (CBT) or interpersonal psy-
chotherapy (IPT) should be considered as first-line treat-
ment for adolescents with depressive symptoms and
mild to moderate depression. Pharmacological treatment
(e.g. SSRIs) should be considered for acute, short-term
reduction of depressive symptoms in adolescents with
moderate to severe MDD [44,45]. CBT may be added
to/continued with SSRI therapy in order to reduce the
risk of suicidal ideation and improve functioning in ado-
lescents with severe MDD [43]. However, there are still a
considerable number of adolescents which have not
achieved the response or remission with depression des-
pite receiving the standard treatment recommended by
these guidelines. Unfortunately, the paucity of studies on
how to manage TRD in adolescents reveals a gap be-
tween the current knowledge base and the need for
evidence-based data to guide clinical care.
According to the findings from TORDIA, switching to
an antidepressant (SSRI or SNRI) in combination with
CBT was superior (54.8%) to switching to medication
alone (40.5%). These results are generally consistent with a
previous Cochrane meta-analysis that showed combin-
ation therapy (65.9%) to be more effective than antidepres-
sant medication alone (57.8%), yet the benefit from
combination therapy did not reveal a significant difference
(OR = 1.56, 95% CI, 0.99-2.27) [46]. However, it should be
noted in the TORDIA trial [36], the medication-only con-
dition actually had “clinical management” sessions during
the acute phase that might have had active “psychother-
apy-like” components (e.g., encouragement, assessment).
Moreover, the CBT in the acute phase of TORDIA trial
was relatively weak for such a severe variant of depression
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show a modest benefit from combination therapy, the dos-
ages of psychotherapy needed for adolescent TRD should
be further studied [12,47].
In another RCT that was judged to be of higher-quality
[34], amitriptyline did not appear to be significantly effica-
cious for adolescents with severe TRD despite the high re-
sponse rate to TCA therapy. The high response rate of
amitriptyline may have been associated with other features
of the study (e.g., intensive inpatient, milieu therapy). A
previous RCT of amitriptyline for the treatment of adoles-
cents with MDD revealed similar findings regarding the
efficacy of amitriptyline [48]. Due to the limited clinical
benefits and significant side effects associated with TCA
use, TCA drugs should not be recommended for use in
the management of adolescent TRD [38].
All statements on the efficacy of treatments must be
tempered by the potential biases and uncertainties that
result from the choice of patients and therapies. In our
analysis, those patients with multi-drug-resistant TRD
showed a high response rate, and patients with SSRI-
resistant TRD appeared to display a higher response rate
than those with TCA-resistant TRD.
Limitations
Several limitations to this systematic review should be
noted. First, the summary response rates were derived
primarily from open-label studies and only two RCTs, so
they should be considered in light of these evolving find-
ings. Second, although we chose the minimum criteria
from the NICE Clinical Guidelines, there are different
definitions of treatment resistance in adolescent TRD.
National Collaborating Centre for Mental Health
(NCCMH), 2005 [12] Our treatment refractory criteria
were inclusive to ensure that we considered a broad range
of evidence, but consequently there was a high degree of
heterogeneity in the included studies. Third, trial dura-
tions ranged from three weeks to sixteen weeks, and few
studies were less than six weeks in duration. Thus, the
relatively short duration in the included studies may have
led to an underestimation of treatment efficacy.
Conclusions
Among adolescent depressed patients, the failure to re-
spond to conventional treatment is common, yet there is a
paucity of data on which evidence-based treatment deci-
sions can be made. In this systematic review of TRD
adolescents who had failed to respond to at least one anti-
depressant or combination psychotherapy, half of patients
responded adequately to active treatment. These findings
suggest that TRD in adolescents requires more patience,
persistence, and systematic effort than adolescent MDD.
The TORDIA trial suggests that an antidepressant (SSRI/
SNRI) plus CBT has a significant additional benefit overantidepressant therapy alone in refractory adolescents.
However, high-quality RCTs comparing therapies for TRD
in adolescents with a more intensive array of psychother-
apy dosages are needed to improve the evidence base for
this debilitating illness. Also, it is emphasized that not only
are there a paucity of studies on how best to manage TRD,
the current guidelines and the implicit sequence of care
embedded within them are not empirically based. Our
field would benefit from studies that directly evaluate se-
quences of care.
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